← Human Trials & Peer-Reviewed Studies

Weight loss-independent changes in human growth hormone during water-only fasting: a secondary evaluation of a randomized controlled trial.

Plain-language guide to PMID 39991046 (2024): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID
39991046
Journal
Frontiers in endocrinology
Year
2024
Study type
Randomized Controlled Trial
Authors
Horne BD et al. (8 authors)
DOI
10.3389/fendo.2024.1401780
Registered trial
NCT01059760

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Human growth hormone (HGH) may play a key role in multiple fasting-triggered mechanisms.

Whether HGH changes during fasting are independent of weight loss and how basal HGH and HGH change relate to other fasting-induced changes are unknown.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

Apparently healthy individuals (N=30) were randomized by Latin square to begin two days with either 24-hour water-only fasting or a control of 24-hour ad libitum eating.

On day 2, subjects were crossed over to control (if day 1 was fasting) or fasting (if they ate on day 1).

How the Study Was Run

In design terms this was a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

HGH, weight, and other parameters were measured at baseline and at the end of the first and second days.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Fasting, Human Growth Hormone, Insulin, Water and Weight Loss.

Author keywords: extended fasting, intermittent fasting, periodic fasting, prolonged fasting and weight-loss.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.